Syntonix was formed to discover and develop novel therapeutic proteins for treatment of chronic diseases such as hemophilia, anemia, multiple sclerosis, and autoimmune disorders.
Biogen IDEC, which acquired Syntonix in 2007, is developing Syntonix’s lead product, recombinant factor IX Fc fusion protein (rFIXFc) for the treatment of hemophilia B. The Syntonix product is the first product candidate in a new class of long-lasting clotting factor therapies that are being developed with the goals of reducing the burden of treatment for this condition and enhancing protection from bleeding. In early 2013 Biogen IDEC submitted a Biologics License Application (BLA) to the FDA for the marketing approval of rFIXFc.
Syntonix was acquired by BiogenIDEC in 2007.
© 2018 Pappas Capital, LLC. ALL RIGHTS RESERVED.